Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

SML3795

Sigma-Aldrich

BAY-3827

≥98% (HPLC)

Synonym(s):

AMPK inhibitor BAY3827, BAY 3827, N-[5-(3,5-Dicyano-1,2,6-trimethyl-1,4-dihydropyridin-4-yl)-6-fluoro-7-methyl-1H-indazol-3-yl]-2-ethylbenzamide, N-[5-(3,5-Dicyano-1,4-dihydro-1,2,6-trimethyl-4-pyridinyl)-6-fluoro-7-methyl-1H-indazol-3-yl]-2-ethylbenzamide

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C27H25FN6O
CAS Number:
2377576-35-5
Molecular Weight:
468.53
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

N#CC1=C(N(C(C)=C(C#N)C1C2=CC3=C(NN=C3NC(C4=C(C=CC=C4)CC)=O)C(C)=C2F)C)C

Biochem/physiol Actions

BAY-3827 is a selective and potent inhibitor of AMPK (AMP-activated protein kinase) and RSK1 (ribosomal 6 kinase 1) that exhibit strong anti-proliferative activity in androgen-dependent prostate cancer cell lines. BAY-3827 strongly down-regulates lipase E (LIPE), cAMP-dependent protein kinase type II-beta regulatory subunit (PRKAR2B), serine-threonine kinase AKT3 and carnitine palmitoyl-transferase 1 (CPT1) family expression levels and impairs lipid flux.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models
Cellular oncology, 44(3), 581-594 (2021)
Rab8a as a mitochondrial receptor for lipid droplets in skeletal muscle
Developmental Cell, 58(4), 289-305 (2023)
Anti-Na+/K+-ATPase DR antibody attenuates UUO-induced renal fibrosis through inhibition of Na+/K+-ATPase ?1-dependent HMGB1 release
Zheng J, Lan P, Li M, Kang MC, Xun M, Ma X, Yan M, Sun D, Shen Y, Fu X, Ding X, Yan X, Xue WJ
International Immunopharmacology, 116, 109826-109826 (2023)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service